 |
24 Diseases |  |
4 Trials |
|
4 Trials |  |
245 News |  |
| «123» |
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Retrospective data, Journal: Clinical and laboratory characteristics of hemophagocytic lymphohistiocytosis induced by Leishmania infantum infection. (Pubmed Central) - Jan 5, 2022
The parasite culturing and qPCR detection of bone marrow samples facilitates the diagnosis of VL associated HLH in addition to other findings of HLH. Prompt treatment with anti-Leishmania and immunosuppressive chemotherapy is critical to reduce the mortality of VL associated HLH.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Journal: Pediatric Cutaneous Leishmaniasis: A Clinico-Epidemiological Study from North India. (Pubmed Central) - Dec 24, 2021
Intralesional or systemic sodium stibogluconate (SSG) was the treatment modality used for the management of patients...CL is an emerging health problem in the pediatric population of Jammu and Kashmir. Awareness among pediatric health workers regarding this disease and recognition among the differential diagnosis of ulcerated papules or plaques in the pediatric population is imperative.
- | Lenocta (sodium stibogluconate) / VioQuest
Journal, PD(L)-1 Biomarker, IO biomarker: Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis. (Pubmed Central) - Dec 21, 2021
Pentavalent antimonials (e.g., sodium stibogluconate [SSG]) remain first-line drugs for CL with no new effective treatments emerging...Our data support a model whereby the initial anti-leishmanial activity of antimonial drugs alleviates checkpoint inhibition on T cells, facilitating immune-drug synergism and clinical cure. Our findings demonstrate that PD-L1 expression can be used as predictor of rapidity of clinical response to SSG treatment in Sri Lanka and support further evaluation of PD-L1 as a host directed therapy target in leishmaniasis.
- | Lenocta (sodium stibogluconate) / VioQuest
Journal: Treatment failure to sodium stibogluconate in cutaneous leishmaniasis: A challenge to infection control and disease elimination. (Pubmed Central) - Dec 16, 2021
The findings highlight the need for in depth investigations on pathogenesis of TF and importance of reviewing existing treatment protocols to introduce more effective strategies. Such interventions would enable containment of the rapid spread of L.donovani infections in Sri Lanka that threatens the ongoing regional elimination drive.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, PK/PD data, Journal: Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients. (Pubmed Central) - Nov 29, 2021
Such interventions would enable containment of the rapid spread of L.donovani infections in Sri Lanka that threatens the ongoing regional elimination drive. The developed model provides detailed insight into the pharmacokinetic differences among Eastern African countries and India, however the resulting differences in paromomycin exposure do not seem to explain the geographical differences in paromomycin efficacy in the treatment of VL patients.
- | Lenocta (sodium stibogluconate) / VioQuest
Retrospective data, Journal: Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia. (Pubmed Central) - Nov 29, 2021
Our data are consistent with previous reports and confirms effectiveness of SSG/PM treatment regimen in the Eastern African countries. Efficacy at 6-months (93.9%) was estimated on data derived from patients who completed follow up and needs to be interrogated by future studies.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Journal: Assessment of serum amylase, lipase and associated factors among patients with visceral leishmaniasis treated with sodium stibogluconate/paromomycin at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia. (Pubmed Central) - Nov 24, 2021
In this study, the level of serum amylase and lipase at treatment of cure was higher and there was an increase in mean serum amylase and lipase after a patient taking sodium stibogluconate and paromomycin combined drugs. Consequently, the elevated result of these biochemical profiles mainly associated with drug induced adverse effect and associated risk factors in VL patients.
- | Lenocta (sodium stibogluconate) / VioQuest
Journal: GC-MS screening and antiparasitic action of Putranjiva roxburghii leaves against sensitive and resistant strains of Leishmania donovani. (Pubmed Central) - Nov 21, 2021
It was found to be safer in cytotoxicity assay and generated ROS mediated oxidative stress in the parasitic cells which was evidenced by the increased and decreased levels of superoxide radicals, lipid peroxidation products, lipid bodies and levels of thiol, plasma membrane integrity respectively. Therefore, our results support the importance of P. roxburghii as a medicinal plant against L. donovani and showed potential for exploration as an antileishmanial agent.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Review, Journal: Efficacy and safety of Pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review. (Pubmed Central) - Nov 4, 2021
The drug may still have a role in the treatment of any form of human leishmaniasis when the first-line option has failed or in patients who cannot tolerate other drugs also in the context of travellers or migrants. In difficult cases, the drug can also be considered as a component of a combination treatment regimen.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Journal: Genome wide comparison of Leishmania donovani strains from Indian visceral leishmaniasis and para-Kala azar dermal leishmaniasis patients. (Pubmed Central) - Oct 10, 2021
In the present study, whole genome sequencing is performed with sodium stibogluconate (SSG) sensitive and resistant L. donovani strains along with SSG sensitive para-KDL strains, derived from the clinical isolates of Indian patients to identify the genomic variations among them...Such distinguishing genomic changes among the para-KDL strains could be significant for the parasites to become dermatotropic. Overall, the study reveals a possible correlation of the development of SSG resistance and the transition towards the manifestation of PKDL with chromosome aneuploidy and non-synonymous genetic variations in the coding sequences of the L. donovani strains from Indian patients.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Journal: Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia. (Pubmed Central) - Sep 15, 2021
P=N/A
Overall, the study reveals a possible correlation of the development of SSG resistance and the transition towards the manifestation of PKDL with chromosome aneuploidy and non-synonymous genetic variations in the coding sequences of the L. donovani strains from Indian patients. Based on miltefosine's good initial response, tolerable side-effects, tablet-form, we propose to include miltefosine for future clinical trials using extended treatment schedules, combination therapy, or targeting specific subgroups.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Journal: Comparison between cutaneous leishmaniasis patients with facial and non-facial lesions. (Pubmed Central) - Aug 20, 2021
In contrast, the two groups were similar regarding clinical characteristics and outcome. These findings suggest differences in disease severity perception by patients and physicians.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Journal: Disseminated Cutaneous Leishmaniasis in a Pediatric Patient from Peru. (Pubmed Central) - Aug 13, 2021
These findings suggest differences in disease severity perception by patients and physicians. Disseminated cutaneous leishmaniasis is a clinical form that is described with increasing frequency and should be recognized and treated appropriately, mainly in the pediatric population, avoiding complications and sequelae.
- | Lenocta (sodium stibogluconate) / VioQuest
Journal: Identification of potential anti-leishmanial agents using computational investigation and biological evaluation against Trypanothione reductase. (Pubmed Central) - Jun 30, 2021
Some of the drugs previously reported against the disease include sodium stibogluconate, miltefosine and amphotericin B. However, due to the resistance and toxicity problem associated with these molecules, there is an urgent need to develop new drugs against L. donovani...Enzyme inhibition assay resulted in shortlisting of four compounds that were found to inhibit Trypanothione reductase of Leishmania Donovani. Subsequently, the anti-leishmanial screening highlighted one compound as the potential anti-leishmanial agent, with IC value of 15.2µM, that can be further optimised with medicinal chemistry efforts to improve its activity.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Journal: Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients. (Pubmed Central) - Jun 24, 2021
Side-effects related to the medication were minimal. In conclusion, miltefosine treatment for paediatric patients with cutaneous leishmaniasis caused by Leishmania tropica or Leishmania major is effective and safe, even in recalcitrant cases.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Journal: Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients. (Pubmed Central) - Jun 24, 2021
In conclusion, oral miltefosine may be an effective and safe treatment for Old World cutaneous leishmaniasis caused by Leishmania tropica or Leishmania major in children. However, further studies are warranted to draw a definite conclusion.
- || Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Lenocta (sodium stibogluconate) / VioQuest
Clinical, Retrospective data, Journal: Comparative assessment of interventions for treating cutaneous leishmaniasis: A network meta-analysis of randomized clinical trials. (Pubmed Central) - Jun 24, 2021
We observed several interventions to be effective for treating cutaneous leishmaniasis. However, greater caution is required in interpreting the results as the estimates are likely to change with the advent of results from future studies.
- | Lenocta (sodium stibogluconate) / VioQuest
Journal: Leishmaniasis in Norway. (Pubmed Central) - Jun 16, 2021
The patients were diagnosed late in the disease course, presumably because the disease is rare and not well known in Norway. Cutaneous leishmaniasis was diagnosed with PCR, but none of the patients received local treatment as the first-line choice, as recommended in suitable cases, presumably because the drugs are not readily available in Norway and many clinicians are unfamiliar with the route of administration with local infiltration.
- | Lenocta (sodium stibogluconate) / VioQuest
Trial completion, Head-to-Head: Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa (clinicaltrials.gov) - Jun 11, 2021
P3, N=439, Completed, Sponsor: Drugs for Neglected Diseases
Cutaneous leishmaniasis was diagnosed with PCR, but none of the patients received local treatment as the first-line choice, as recommended in suitable cases, presumably because the drugs are not readily available in Norway and many clinicians are unfamiliar with the route of administration with local infiltration. Active, not recruiting --> Completed
- | Lenocta (sodium stibogluconate) / VioQuest
New P2 trial: Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations (clinicaltrials.gov) - May 28, 2021
P2, N=5, Recruiting, Sponsor: First Affiliated Hospital of Jinan University
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Retrospective data, Review, Journal: Clinical and epidemiological review of tegumentary leishmaniasis in a central region of Peru (Pubmed Central) - May 22, 2021
The eco-environmental conditions of this area of Peru have allowed the establishment of tegumentary leishmaniasis; showing trends similar to world literature. However, more research is needed to explain the epidemiological behavior of this disease that allows the creation of epidemiological prediction models for timely and adequate control.
- amphotericin b liposome / Generic mfg.
[VIRTUAL] Cutaneous Leishmaniasis in India: Diagnostic Efficacy of Antigen-based Immunochromatographic Test and Response to Treatment with Liposomal Amphotericin B (Poster Hall) - May 9, 2021 - Abstract #WMF2021WMF_2061;
This study highlights the appreciable sensitivity of rapid detection method, combined with real-time PCR for a less invasive and efficient diagnostic approach of cutaneous leishmaniasis. LAmB, is known for its exemplary efficacy for treatment of VL and Post kala-azar dermal leishmaniasis, maybe resorted for treatment, pertaining to the high efficacy in healing and absence of incidences of recurrence in CL patients.
- || Lenocta (sodium stibogluconate) / VioQuest, AmBisome (amphotericin b liposome) / Gilead, Grupo Biotoscana, Sumitomo Dainippon, Astellas
Clinical, Review, Journal: Therapeutic Modalities in Post Kala-azar Dermal Leishmaniasis: A Systematic Review of the Effectiveness and Safety of the Treatment Options. (Pubmed Central) - Apr 30, 2021
Kala-azar continues to haunt the tropical countries and PKDL being its reservoir is threatening its elimination. With the availability of drugs such as liposomal amphotericin B and miltefosine, apart from the advent of immunotherapy, the future of treatment of this condition looks promising.
- | Lenocta (sodium stibogluconate) / VioQuest
Journal: Synergistic Effect Of Oral Allopurinol And Intralesional Sodium Stibogluconate In The Treatment Of Cutaneous Leishmaniasis. (Pubmed Central) - Apr 27, 2021
Oral Allopurinol has a synergistic effect when used with intra-lesional sodium Stibogluconate and effectively reduces the treatment duration required for complete cure of cutaneous Leishmaniasis. Treatment duration was reduced by 3 weeks in the present study when combination therapy was given to the patients of cutaneous Leishmaniasis.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Journal: Clinical and Epidemiological study of Cutaneous Leishmaniasis from two tertiary care hospitals of Jammu and Kashmir: an Emerging Disease in North India. (Pubmed Central) - Mar 26, 2021
Treatment duration was reduced by 3 weeks in the present study when combination therapy was given to the patients of cutaneous Leishmaniasis. With the disease showing an escalating trend in Jammu and Kashmir, the possibility of a new focus of endemicity and its impact on public health need to be contemplated, and appropriate measures should be initiated to contain its spread.
- || rifampicin / Generic mfg.
Clinical, Journal: The co-infection of Buruli ulcer and cutaneous leishmaniasis in Sudanese patient: An association by choice or by chance? (Pubmed Central) - Mar 16, 2021
Treatment with streptomycin intramuscular injections 1g daily and rifampicin 600mg daily for 8 weeks was associated with complete healing of the ulcer. To our knowledge, this is the first report that describes the co-infection of Buruli ulcer and cutaneous leishmaniasis in Sudan.
- || Lenocta (sodium stibogluconate) / VioQuest, AmBisome (amphotericin b liposome) / Gilead, Grupo Biotoscana, Sumitomo Dainippon, Astellas
Clinical, Review, Journal: Visceral leishmaniasis in Saudi Arabia: from hundreds of cases to zero. (Pubmed Central) - Mar 4, 2021
After reaching a zero case in 2019, the Ministry of Health (MoH) has a new commitment and facing a great challenge which are maintenance of current situation and elimination of VL. Through the support of stakeholders, encouragement of community participation, preparedness and readiness of leishmaniasis personnel, the new mission of the NLCP now is elimination of the scourge of VL from the country.
- | Lenocta (sodium stibogluconate) / VioQuest
Enrollment open: Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia (clinicaltrials.gov) - Mar 3, 2021
P=N/A, N=117, Recruiting, Sponsor: Institute of Tropical Medicine, Belgium
Through the support of stakeholders, encouragement of community participation, preparedness and readiness of leishmaniasis personnel, the new mission of the NLCP now is elimination of the scourge of VL from the country. Not yet recruiting --> Recruiting
- | Lenocta (sodium stibogluconate) / VioQuest
Journal: Identification of Phenylphthalazinones as a New Class of Leishmania infantum Inhibitors. (Pubmed Central) - Jan 23, 2021
Current treatments often rely on harsh regimes of pentavalent antimonials such as sodium stibogluconate, while more recent drugs suffer other shortcomings such as low stability and rapid emergence of treatment failure, amongst others...Replacement of the unsubstituted 2,3-pyrazole with 1,2,3-triazoles led to compounds with lower anti-leishmanial activity. The current scaffold is a valuable new starting point for optimization towards novel anti-leishmanial drugs.
- | Lenocta (sodium stibogluconate) / VioQuest
New trial: Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia (clinicaltrials.gov) - Jan 7, 2021
P, N=117, Not yet recruiting, Sponsor: Institute of Tropical Medicine, Belgium
- | Lenocta (sodium stibogluconate) / VioQuest
Preclinical, Journal: Comparison of in vitro Resistance of Wild Leishmania İsolates, Which are Resistant to Pentavalent Antimonial Compounds, Against Drugs Used in the Treatment of Leishmaniasis (Pubmed Central) - Jan 2, 2021
Meglumine antimoniate (Glucantime) and Sodium stibogluconate (Pentostam) are used for the treatment of cutaneous leismaniasis in Turkey...It was determined that none of the selected resistant L. tropica isolates showed resistance to Amphotericin B and that was also shown statistically (p<0.05). The results of this study are important in guiding clinicians and researchers who conduct studies on drugs and search for new drug molecules.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Journal: Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs. (Pubmed Central) - Dec 30, 2020
In addition, all dogs were classified as parasite negative based on Leishmania nested PCR and quantitative real time PCR tests and as well as an inability to culture of promastigote parasites from lymph nodes and bone marrow tissue samples taken at day 90 post-treatment. However, treatment did not cure the dogs as parasites were detected at 10 months post-treatment, indicating that a different dosing regimen is required to cause long term cure or prevent relapse.
- | Lenocta (sodium stibogluconate) / VioQuest
Journal: Nano-elastic liposomes as multidrug carrier of sodium stibogluconate and ketoconazole: A potential new approach for the topical treatment of cutaneous leishmaniasis. (Pubmed Central) - Nov 27, 2020
In-vitro and in-vivo anti-leishmanial studies indicated a 10.67-fold lower IC value and a 35.33-fold reduced parasitic burden as compared with plain SSG solution, respectively. SSG-KTZ co-loaded NELs were found to be a promising approach for the topical treatment of CL.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Journal: Cutaneous Leishmaniasis: Case Series on Pregnancy Outcome. (Pubmed Central) - Nov 21, 2020
No teratogenic effects were reported. Furthermore, no vertical transmission was observed.
- Lenocta (sodium stibogluconate) / VioQuest
[VIRTUAL] A Clinical audit on cutaneous leishmaniasis response to Sodium stibogluconate among patients attending dermatology units, National Hospital of Sri Lanka () - Oct 20, 2020 - Abstract #EADV2020EADV_2243;
- | cyclosporine / Generic mfg.
Preclinical, Journal: Evaluation of in vitro antileishmanial efficacy of cyclosporin A and its non-immunosuppressive derivative, dihydrocyclosporin A. (Pubmed Central) - Sep 21, 2020
DHCsA-d significantly inhibited promastigotes and intracellular amastigotes, but it was highly cytotoxic. Therefore, CsA and DHCsA-d are not recommended as antileishmanial drugs.
- | Lenocta (sodium stibogluconate) / VioQuest
Journal: Using Q-methodology to understand the perspectives and practical experiences of dermatologists about treatment difficulties of cutaneous leishmaniasis. (Pubmed Central) - Sep 11, 2020
More research is required to determine the best treatment modalities for the different types of cutaneous leishmaniasis. There is a need for the development of treatment guidelines specific to the Iraqi context with a particular focus on the treatment of the resistant and atypical cases of cutaneous leishmaniasis.
- || Lenocta (sodium stibogluconate) / VioQuest, AmBisome (amphotericin b liposome) / Gilead, Grupo Biotoscana, Sumitomo Dainippon, Astellas
Clinical, Journal: Observation on Treatment of Drug Resistant Kala-azar Patients with Fungizone in Patna, Bihar. (Pubmed Central) - Aug 29, 2020
That cases was given treatment for HIV also. The moment he became negative of kala-azar, he fled away.
- | Lenocta (sodium stibogluconate) / VioQuest
Enrollment closed, Trial completion date, Trial primary completion date, Head-to-Head: Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa (clinicaltrials.gov) - Jul 21, 2020
P3, N=439, Active, not recruiting, Sponsor: Drugs for Neglected Diseases
The moment he became negative of kala-azar, he fled away. Recruiting --> Active, not recruiting | Trial completion date: Nov 2019 --> Dec 2020 | Trial primary completion date: Nov 2019 --> Dec 2020
- | Lenocta (sodium stibogluconate) / VioQuest
Journal: Gold-Silver Bimetallic Nanoparticles Reduced with Herbal Leaf Extracts Induce ROS-Mediated Death in Both Promastigote and Amastigote Stages of Leishmania donovani. (Pubmed Central) - Jul 15, 2020
Resistance to antileishmanial drugs such as sodium stibogluconate (SSG), amphotericin B (Amp-B), and miltefosine is on the rise, and alternate strategies for effective treatment have gained importance in recent years...The intracellular amastigotes were reduced by 31-46% in macrophages. The biogenic BNPs synthesized in this study and their potent antileishmanial activity provide further impetus to the ongoing quest for novel drugs to effectively manage leishmaniasis.
- Lenocta (sodium stibogluconate) / VioQuest
[VIRTUAL] Treatment-refractory cutaneous leishmaniasis in an 8-year-old migrant from central Afghanistan () - Jun 20, 2020 - Abstract #AADVMX2020AAD-VMX_231;
In Afghanistan, he was diagnosed with cutaneous leishmaniasis (CL) and had no improvement after intralesional meglumine antimoniate and intramuscular sodium stibogluconate...Early diagnosis and treatment is vital to minimize disfigurement. Given international large-scale migrations in recent years, it is critical to maintain awareness of cutaneous manifestations of infectious diseases endemic to other global regions.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Journal: Chemogenomic profiling of anti-leishmanial efficacy and resistance in the related kinetoplastid parasite Trypanosoma brucei. (Pubmed Central) - Jun 10, 2020
Forward genetic approaches have revolutionized our understanding of drug mode of action in the related kinetoplastid parasite Trypanosoma brucei Therefore, we screened our genome-scale T. brucei RNA interference (RNAi) library against the current antileishmanial drugs sodium stibogluconate (antimonial), paromomycin, miltefosine, and amphotericin B. Identification of T. brucei orthologues of the known Leishmania antimonial and miltefosine plasma membrane transporters effectively validated our approach, while a cohort of 42 novel drug efficacy determinants provides new insights and serves as a resource...Finally, multiple phospholipid-transporting flippases, including the T. brucei orthologue of the Leishmania miltefosine transporter, a putative β-subunit/CDC50 co-factor, and additional membrane-associated hits, affect amphotericin-B efficacy, providing new insights into mechanisms of drug uptake and action. The findings from this orthology-based chemogenomic profiling approach substantially advance our understanding of anti-leishmanial drug action and potential resistance mechanisms, and should facilitate the development of improved therapies, as well as surveillance for drug-resistant parasites.
- | Lenocta (sodium stibogluconate) / VioQuest, pentamidine oral (VLX103) / Verlyx, AmBisome (amphotericin b liposome) / Gilead, Grupo Biotoscana, Sumitomo Dainippon, Astellas
Journal: Novel Synthetic Approaches for Bisnaphthalimidopropyl (BNIP) Derivatives as Potential Anti-Parasitic Agents for the Treatment of Leishmaniasis. (Pubmed Central) - May 25, 2020
The new synthesis approach provides certain advantages compared to its existing alternatives reported in the literature. The proposed methodology does not only decrease the number of synthesis steps and production time of BNIPDaoct and BNIPDanon, but also provides higher yields, thereby making the synthesis highly cost-effective.
- | Lenocta (sodium stibogluconate) / VioQuest
Journal: Infectivity and Drug Susceptibility Profiling of Different Leishmania-Host Cell Combinations. (Pubmed Central) - May 24, 2020
In the drug susceptibility test, miltefosine and sodium stibogluconate (SSG) showed varying ranges of activity with 14 and >10-fold differences in susceptibility, depending on the host-parasite pairs, indicating the importance of assay conditions for evaluating antileishmanial activity. Overall, our results suggest that combinations of Leishmania species, infection forms, and host cells must be carefully optimized to evaluate the activity of potential therapeutic compounds against Leishmania.
- || Lenocta (sodium stibogluconate) / VioQuest
Clinical, Journal: The Efficacy and Safety of Intralesional Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis in Children under the Age of Two Years. (Pubmed Central) - May 14, 2020
Overall, our results suggest that combinations of Leishmania species, infection forms, and host cells must be carefully optimized to evaluate the activity of potential therapeutic compounds against Leishmania. No abstract available
- | Lenocta (sodium stibogluconate) / VioQuest
Journal: CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis. (Pubmed Central) - Apr 28, 2020
Results show that macaques treated with D35 plus 5mg/kg sodium stibogluconate (SbV) for 10 days had smaller lesions and reduced time to re-epithelization after infection with Leishmania major...Critically, pentavalent antimonial treatment did not modify the ability of D35 to induce type I IFNs. The findings support the efficacy of D35 as adjuvant therapy for shorter, low dose pentavalent antimonial treatment.
- | Lenocta (sodium stibogluconate) / VioQuest
Journal: Characterization of visceral leishmaniasis outbreak, Marsabit County, Kenya, 2014. (Pubmed Central) - Apr 26, 2020
VL case management sensitization training was conducted. The County health department should put in place one health VL surveillance and facilitate periodic case management trainings.
- | Lenocta (sodium stibogluconate) / VioQuest
New trial: A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis (clinicaltrials.gov) - Apr 13, 2020
P, N=280, Not yet recruiting, Sponsor: University of York
- | Review, Journal: Important roles of Protein Tyrosine Phosphatase PTPN12 in Tumor Progression. (Pubmed Central) - Mar 24, 2020
According to its newly identified roles and functions, PTPN12 is considered a promising therapeutic target against critical diseases, including cancer, diabetes, metabolic disease and autoimmune diseases. In this review, we provide an overview of PTPs and discuss the critical roles of PTPN12/PTP-PEST in tumor progression.
- || Lenocta (sodium stibogluconate) / VioQuest, AmBisome (amphotericin b liposome) / Gilead, Grupo Biotoscana, Sumitomo Dainippon
Clinical, Journal: Epidemiology and Spatiotemporal Analysis of Visceral Leishmaniasis in Palestine from 1990 to 2017. (Pubmed Central) - Mar 24, 2020
Pentavalent antimonial sodium stibogluconate continues to be the first line treatment and physicians are recommended to consider liposomal Amphotericin B (AmBisome) for refractory patients only. Geographical, spatiotemporal and seasonal trends of VL were identified.